UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Ipsen’s Dysport.

Dysport is an injectable form of a botulinum neurotoxin type A product now used for treating focal spasticity of upper limbs in pediatric cerebral palsy patients, indicated for use on children aged two years and above.

Related Company Profiles

View all

MHRA decision comes from findings of Phase III study of Dysport involving 210 children aged two to 17 years.

According to Ipsen, administering Dysport reduced spasticity symptoms among the subjects, with data measured by the standard scale for assessing muscle resistance associated with spasticity, Modified Ashworth Scale (MAS).

Ipsen UK & Ireland general manager Asad Mohsin Ali said: “Today’s approval is an important advancement for children in the UK living with cerebral palsy, who can now benefit from long-lasting symptom relief between their botulinum toxin A injections.

“As a father myself, I am proud that Ipsen is the first company to have obtained this approval that may help children live as normal a life as possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Spasticity refers to involuntary muscle stiffness or contractions in a group of muscles. Cerebral palsy (CP) is one of the leading causes of spasticity among children.

In the UK, around one in 400 babies have a type of CP. Around 90% of them will develop spastic cerebral palsy, affecting their motor skills and movement abilities.

Ipsen is a French pharmaceutical company, which primarily develops medicines in oncology, neuroscience and rare disease therapeutic areas.

Last year, the company acquired Canada-based Clementia Pharmaceuticals for nearly $1bn.